Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition

Published:2019-12 Issue: Volume:184 Page:44-49
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Ramacciotti Eduardo^ORCID,Weitz Jeffrey I.

Funder

Pfizer

Boehringer Ingelheim

Bayer

Publisher

Elsevier BV

Subject

Hematology

Reference33 articles.

1. Heart disease and stroke statistics-2018 update: a report from the American Heart Association;Benjamin;Circulation,2018

2. Platelets and thrombin generation;Monroe;Arterioscler. Thromb. Vasc. Biol.,2002

3. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology;Task Force M;Eur. Heart J.,2013

4. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit;Rothberg;Ann. Intern. Med.,2005

5. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease;Warfarin Antiplatelet Vascular Evaluation Trial I;N. Engl. J. Med.,2007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral Arterial Disease and the Pharmacist’s Role in Management;Journal of Clinical Pharmacy and Therapeutics;2023-08-11

2. Antithrombotic Therapy to Reduce Mortality in Patients With Atherosclerosis;Journal of the American College of Cardiology;2021-07

3. Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy;Current Cardiology Reviews;2021-05-21

4. Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis;Current Drug Targets;2021-03-10

5. Age and Origin of the Founder Antithrombin Budapest 3 (p.Leu131Phe) Mutation; Its High Prevalence in the Roma Population and Its Association With Cardiovascular Diseases;Frontiers in Cardiovascular Medicine;2021-02-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3